{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:00:33Z","timestamp":1778680833223,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"7th Framework Program of the European Union FIGHT-MG","award":["242210"],"award-info":[{"award-number":["242210"]}]},{"name":"Israel Ministry of Health Chief Scientist Fund"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.jaut.2013.12.017","type":"journal-article","created":{"date-parts":[[2014,1,11]],"date-time":"2014-01-11T15:31:29Z","timestamp":1389454289000},"page":"36-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Tissue plasminogen activator involvement in experimental autoimmune myasthenia gravis: Aggravation and therapeutic potential"],"prefix":"10.1016","volume":"52","author":[{"given":"Devorah","family":"Gur-Wahnon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tehila","family":"Mizrachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Wald-Altman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abd Al-Roof","family":"Higazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talma","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2013.12.017_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.neuropharm.2011.10.020","article-title":"tPA in the injured central nervous system: different scenarios starring the same actor?","volume":"62","author":"Lemarchant","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jaut.2013.12.017_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/187221413804660962","article-title":"tPA in the central nervous system: relations between tPA and cell surface LRPs","volume":"7","author":"Ortolano","year":"2013","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"10.1016\/j.jaut.2013.12.017_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2821","article-title":"Regulation of cell signalling by uPAR","volume":"11","author":"Smith","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jaut.2013.12.017_bib4","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.thromres.2012.06.023","article-title":"The biochemistry, physiology and pathological roles of PAI-1 and the requirements for PAI-1 inhibition in\u00a0vivo","volume":"130","author":"Van De Craen","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jaut.2013.12.017_bib5","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/sj.emboj.7601082","article-title":"Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration","volume":"25","author":"Cao","year":"2006","journal-title":"EMBO J"},{"key":"10.1016\/j.jaut.2013.12.017_bib6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2141.2012.09074.x","article-title":"PAI-1, progress in understanding the clinical problem and its aetiology","volume":"157","author":"Iwaki","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaut.2013.12.017_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jaut.2013.12.017_bib8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaut.2013.12.017_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00005-011-0158-6","article-title":"Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?","volume":"60","author":"Baggi","year":"2012","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.jaut.2013.12.017_bib10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3109\/08916930903518081","article-title":"Development of novel therapies for MG: studies in animal models","volume":"43","author":"Souroujon","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaut.2013.12.017_bib11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/WCO.0b013e32833cc968","article-title":"Autoimmune mediated neuromuscular junction defects","volume":"23","author":"Farrugia","year":"2010","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.jaut.2013.12.017_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3988\/jcn.2011.7.4.173","article-title":"Treatment of myasthenia gravis based on its immunopathogenesis","volume":"7","author":"Kim","year":"2011","journal-title":"J\u00a0Clin Neurol"},{"key":"10.1016\/j.jaut.2013.12.017_bib13","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.autrev.2013.03.003","article-title":"Complement associated pathogenic mechanisms in myasthenia gravis","volume":"12","author":"Tuzun","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaut.2013.12.017_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm.2622","article-title":"Re-establishing immunological self-tolerance in autoimmune disease","volume":"18","author":"Sakaguchi","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jaut.2013.12.017_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2567.2005.02220.x","article-title":"Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment","volume":"116","author":"Fattorossi","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.jaut.2013.12.017_bib16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2013.12.017_bib17","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.4049\/jimmunol.180.4.2132","article-title":"Ex\u00a0vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis","volume":"180","author":"Aricha","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.017_bib18","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.autrev.2013.03.009","article-title":"Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model","volume":"12","author":"Gertel-Lapter","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaut.2013.12.017_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1074-7613(02)00398-9","article-title":"Dendritic cells, BAFF, and APRIL: innate players in adaptive antibody responses","volume":"17","author":"MacLennan","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2013.12.017_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.05.010","article-title":"Serum BAFF expression in patients with myasthenia gravis","volume":"199","author":"Kim","year":"2008","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.017_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0019-2791(77)90291-9","article-title":"Immunochemical studies on acetylcholine receptor from Torpedo californica","volume":"14","author":"Aharonov","year":"1977","journal-title":"Immunochemistry"},{"key":"10.1016\/j.jaut.2013.12.017_bib22","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.neuropharm.2009.12.017","article-title":"Blood-brain barrier permeability and tPA-mediated neurotoxicity","volume":"58","author":"Abu Fanne","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jaut.2013.12.017_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1742-2094-10-124","article-title":"The plasminogen activator system: involvement in central nervous system inflammation and a potential site for therapeutic intervention","volume":"10","author":"Gur-Wahnon","year":"2013","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.jaut.2013.12.017_bib24","first-page":"986","article-title":"Radioimmunoassay of antibodies to acetylcholine receptor in serum of myasthenia gravis patients","volume":"14","author":"Brenner","year":"1978","journal-title":"Isr J Med Sci"},{"key":"10.1016\/j.jaut.2013.12.017_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.expneurol.2005.11.012","article-title":"Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein","volume":"198","author":"Irony-Tur-Sinai","year":"2006","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jaut.2013.12.017_bib26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2009.01.021","article-title":"Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3","volume":"209","author":"Feferman","year":"2009","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.017_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/berh.1999.0083","article-title":"The anti-phospholipid antibody syndrome (Hughes syndrome): therapeutic aspects","volume":"14","author":"Cuadrado","year":"2000","journal-title":"Baillieres Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jaut.2013.12.017_bib28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0002-9440(10)62996-3","article-title":"A\u00a0role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis","volume":"167","author":"East","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaut.2013.12.017_bib29","first-page":"293","article-title":"Antiphospholipid antibodies and thrombosis: the putative mechanisms of hypercoagulable state in patients with anticardiolipin antibody","volume":"48","author":"Ieko","year":"2000","journal-title":"Rinsho Byori"},{"key":"10.1016\/j.jaut.2013.12.017_bib30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1182\/blood-2003-05-1685","article-title":"In\u00a0vitro and in\u00a0vivo effects of tPA and PAI-1 on blood vessel tone","volume":"103","author":"Nassar","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2013.12.017_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/096120339600500406","article-title":"Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis","volume":"5","author":"Salazar-Paramo","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2013.12.017_bib32","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4049\/jimmunol.167.2.1047","article-title":"Tissue-type plasminogen activator deficiency exacerbates arthritis","volume":"167","author":"Yang","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.017_bib33","first-page":"632","article-title":"Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome","volume":"85","author":"Munoz-Rodriguez","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.jaut.2013.12.017_bib34","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1083\/jcb.200705127","article-title":"uPA deficiency exacerbates muscular dystrophy in MDX mice","volume":"178","author":"Suelves","year":"2007","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.jaut.2013.12.017_bib35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2249.2008.03606.x","article-title":"Immunomodulatory effects of plasminogen activators on hepatic fibrogenesis","volume":"152","author":"Higazi","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaut.2013.12.017_bib36","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI118896","article-title":"Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes","volume":"98","author":"Bianchi","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaut.2013.12.017_bib37","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.4049\/jimmunol.158.3.1051","article-title":"Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering","volume":"158","author":"Gundersen","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.017_bib38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/jlb.51.3.256","article-title":"Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha","volume":"51","author":"Gyetko","year":"1992","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.jaut.2013.12.017_bib39","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/jlb.53.5.598","article-title":"Monocyte urokinase expression: modulation by interleukins","volume":"53","author":"Gyetko","year":"1993","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.jaut.2013.12.017_bib40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4049\/jimmunol.152.2.505","article-title":"Urokinase receptor. An activation antigen in human T lymphocytes","volume":"152","author":"Nykjaer","year":"1994","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.017_bib41","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.4049\/jimmunol.126.4.1415","article-title":"Plasminogen activator is an apparent lymphocyte mitogen","volume":"126","author":"Cohen","year":"1981","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.017_bib42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.4049\/jimmunol.168.2.801","article-title":"Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection","volume":"168","author":"Gyetko","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.017_bib43","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.coi.2007.04.008","article-title":"B\u00a0cells and the BAFF\/APRIL axis: fast-forward on autoimmunity and signaling","volume":"19","author":"Mackay","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaut.2013.12.017_bib44","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.4049\/jimmunol.1001931","article-title":"B\u00a0cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus","volume":"186","author":"Jiang","year":"2011","journal-title":"J\u00a0Immunol"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841113001649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841113001649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:08:21Z","timestamp":1760256501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841113001649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":44,"alternative-id":["S0896841113001649"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2013.12.017","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tissue plasminogen activator involvement in experimental autoimmune myasthenia gravis: Aggravation and therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2013.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}